Calcium channel blockers are medications used to lower blood pressure.


Last week, GCT has been selected to conduct a bioequivalence clinical trial in a calcium channel blocker, Manidipine. The randomized, two treatment, two sequence, two way cross over, bioequivalence study of Manidipine Dihydrochloride tablets will be performed in Ukraine with participation of 30 healthy volunteers.

GCT will manage the full-service study support including medical writing, clinical and medical monitoring, regulatory, project management, site and vendor management, data management and biostatistics.

“We are thrilled to enhance our cardiovascular trials portfolio in Ukraine and to build strong partnership with our new client,” – said Dr. Jeffrey Apter, GCT President.

GCT has deep experience in the management and execution of BE / BA / PK clinical trials, in Ukraine and globally.